Pluri Inc. Files 8-K on Executive and Director Changes
Ticker: PLUR · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1158780
| Field | Detail |
|---|---|
| Company | Pluri Inc. (PLUR) |
| Form Type | 8-K |
| Filed Date | Oct 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001, $5.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-composition, executive-compensation
TL;DR
Pluri Inc. reshuffled its board and execs as of Oct 15, 2025. Details in new 8-K.
AI Summary
Pluri Inc. filed an 8-K on October 16, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing covers events as of October 15, 2025, and pertains to Pluri Inc., a Nevada-based company in the biological products sector.
Why It Matters
This filing indicates potential shifts in the leadership and governance of Pluri Inc., which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors and officers can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Pluri Inc. (company) — Registrant
- Nevada (jurisdiction) — State of Incorporation
- October 16, 2025 (date) — Filing Date
- October 15, 2025 (date) — Date of Earliest Event Reported
FAQ
What specific roles or positions were affected by the changes reported in the 8-K?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
Are there any financial implications mentioned regarding these executive or director changes?
The filing mentions 'Compensatory Arrangements of Certain Officers,' suggesting that changes in compensation may be part of the reported events, though specific dollar amounts are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 15, 2025.
What is the primary business of Pluri Inc. according to the filing?
According to the filing, Pluri Inc. is in the business of 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with a Standard Industrial Classification code of 2836.
What is the filing date of this Current Report (8-K)?
This Current Report (8-K) was filed on October 16, 2025.
Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-10-16 17:03:32
Key Financial Figures
- $0.00001 — h registered Common Shares, par value $0.00001 per share PLUR The Nasdaq Capital M
- $5.00 — of three years at an exercise price of $5.00 per share. The Board further approved,
Filing Documents
- ea0261561-8k_pluri.htm (8-K) — 25KB
- 0001213900-25-099632.txt ( ) — 187KB
- plur-20251015.xsd (EX-101.SCH) — 3KB
- plur-20251015_lab.xml (EX-101.LAB) — 33KB
- plur-20251015_pre.xml (EX-101.PRE) — 22KB
- ea0261561-8k_pluri_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15, 2025, the board of directors (the "Board") of Pluri Inc. approved a grant of equity awards to Yaky Yanay, the Company's Chief Executive Officer (the "CEO"), in recognition of the achievement of certain performance objectives and other accomplishments during fiscal year 2025. The approved equity awards consist of (i) 39,050 restricted stock units ("RSUs") which are fully vested, and (ii) stock options to purchase 39,050 common shares of the Company which are fully vested and exercisable for a period of three years at an exercise price of $5.00 per share. The Board further approved, contingent upon the achievement of certain objectives and accomplishments by December 31, 2025, the future grant to the CEO of (i) 9,266 RSUs, and (ii) stock options to purchase 9,266 common shares of the Company. The grant date of such RSUs and stock options, if awarded, will be the date on which the applicable objectives are satisfied, and the stock options will be exercisable for three years at an exercise price of $5.00 per share. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLURI INC. Date: October 16, 2025 By: /s/ Liat Zalts Name: Liat Zalts Title: Chief Financial Officer 2